NDA 210450 · Abbvie
Orilissa
Elagolix Sodium · Oral
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Dec 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jul 23, 2018
Approved uses
4
Original approval plus efficacy supplements
Registered trials
34
15 Phase 3, 1 recruiting
FAERS reports
3,729
1,319 serious, 6 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 19, 2025.
ORILISSA is indicated for the management of moderate to severe pain associated with endometriosis. Limitation s of Use: Limit the duration of use based on the dose and coexisting condition (see Table 1 ) [see D osage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 ) ] . ORILISSA is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis. ( 1 ) Limitation s of Use: Limit the duration of use based on the dose and coexisting condition (see Table 1 ). ( 1 )
Mechanism: ORILISSA is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of ORILISSA results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 1, 2021 Supplement 6 · Efficacy LetterLabel
- Feb 1, 2021 Supplement 4 · Efficacy LetterLabel
- Feb 1, 2021 Supplement 5 · Efficacy LetterLabel
- Jul 23, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
2 products under this application
- ORILISSA · ELAGOLIX SODIUM EQ 150MG BASE · TABLET, ORAL · Prescription
- ORILISSA · ELAGOLIX SODIUM EQ 200MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Elagolix" as an intervention, any sponsor and status, largest first.
- A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated PainPivotal-lookingCompleted
AbbVie (prior sponsor, Abbott)AbbVie (ABBV)
NCT01620528 · 872 participants · Start May 22, 2012 · Primary completion Nov 14, 2014
Drug: elagolix · For: Endometriosis
- A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated PainPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT01931670 · 815 participants · Start Sep 9, 2013 · Primary completion Jan 6, 2016
Drug: Elagolix · For: Endometriosis
- Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe PainPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT04333576 · 800 participants (planned) · Start Aug 10, 2020 · Primary completion Jul 2027
Drug: Elagolix; Placebo and 1 more · For: Endometriosis
Sites: Anniston, Alabama; Birmingham, Alabama; Dothan, Alabama · 179 sites in all
- A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated PainPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03213457 · 681 participants · Start Jul 7, 2017 · Primary completion Mar 27, 2020
Drug: Estradiol/Norethindrone Acetate; Placebo for Elagolix and 2 more · For: Endometriosis
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 197 sites in all
- Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)Pivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT01817530 · 571 participants · Start Apr 8, 2013 · Primary completion Jun 2015
Drug: Elagolix; 0.5 mg estradiol / 0.1 mg norethindrone acetate and 2 more · For: Heavy Uterine Bleeding; Uterine Fibroids
- Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated PainPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT01760954 · 506 participants · Start Dec 28, 2012 · Primary completion May 2015
Drug: Elagolix · For: Endometriosis
- Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated PainPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT02143713 · 496 participants · Start May 27, 2014 · Primary completion Jun 22, 2016
Drug: Elagolix · For: Endometriosis
- Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal WomenPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03271489 · 478 participants · Start Sep 13, 2017 · Primary completion Jun 28, 2024
Drug: Elagolix; Estradiol /norethindrone acetate (E2/NETA) · For: Heavy Menstrual Bleeding; Uterine Fibroids
Sites: Birmingham, Alabama; Dothan, Alabama; Fairhope, Alabama · 157 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hot flush471
- pain437
- nausea327
- endometriosis304
- headache277
- drug ineffective253
- depression214
- arthralgia200
- anxiety163
- insomnia151
- suicidal ideation148
- adverse drug reaction140
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 49 |
| 2019 | 930 |
| 2020 | 1,090 |
| 2021 | 517 |
| 2022 | 700 |
| 2023 | 223 |
| 2024 | 121 |
| 2025 | 75 |
| 2026 | 24 |
Recalls
1 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Orilissa (Elagolix Sodium)
2024 spending
$3.2M
Beneficiaries
511
2,310 claims
Per beneficiary
$6,174
$36.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,971,696 |
| 2021 | $3,343,652 |
| 2022 | $3,696,413 |
| 2023 | $3,632,354 |
| 2024 | $3,154,831 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS, Giudice LC, Lessey BA, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Pharmacologic Interventions for Endometriosis-Related Pain: A Systematic Review and Meta-analysis.
Kou L, Huang C, Xiao D, et al. · Obstet Gynecol 2025 · Systematic Review, Network Meta-Analysis
- Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial.
Miller CE, Kim JH, Kroll R, et al. · Am J Obstet Gynecol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis.
Sánchez Martín MJ, Huerga López C, Cristóbal García I, et al. · Arch Gynecol Obstet 2025 · Meta-Analysis, Review
- Cost-effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA.
Wang ST, Johnson SJ, Mitchell D, et al. · J Comp Eff Res 2019 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
Schlaff WD, Ackerman RT, Al-Hendy A, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.